Cyclophosphamide

Cancer Treatment

Cyclophosphamide is used to treat various types of cancer, often in combination with other chemotherapy medications. It works by slowing or stopping the growth of cancer cells in the body. Conditions it is used for include:

• Lymphomas: Including Hodgkin's disease and non-Hodgkin's lymphoma.
• Leukemias: Various types of blood and bone marrow cancers, such as chronic lymphocytic leukemia and acute lymphoblastic leukemia.
• Multiple myeloma: A cancer that forms in a type of white blood cell.
• Solid tumors: Including breast cancer, ovarian cancer, neuroblastoma (cancer that develops in nerve cells), and retinoblastoma (an eye cancer).
• Mycosis fungoides: A type of skin lymphoma.

Kidney Disease

In children, cyclophosphamide is used to treat nephrotic syndrome. This is a condition where the kidneys do not work properly and leak large amounts of protein into the urine. It is generally prescribed when the disease has not responded well to other treatments, such as corticosteroids, or when those treatments cause severe side effects.

Mechanism of Action

Cyclophosphamide belongs to a class of drugs called alkylating agents. It works by interfering with the DNA inside cells. DNA is the genetic material that cells need to grow and divide. By damaging the DNA, cyclophosphamide prevents cells from multiplying, which helps to slow or stop the spread of cancer in the body.

Immune System Suppression

In addition to its use in treating cancer, cyclophosphamide acts as an immunosuppressant. It works by decreasing the activity of the immune system. This can be helpful in treating certain autoimmune conditions where the body's natural defenses are overactive or attacking healthy tissues.

Activation in the Body

Cyclophosphamide is considered a prodrug, meaning it is not active when it first enters the body. Once it is taken orally or injected, the liver processes the medication and converts it into active metabolites. These active substances then circulate through the bloodstream to target and affect cells throughout the body.

Common Side Effects

• Nausea and vomiting
• Loss of appetite or stomach pain
• Diarrhea
• Temporary hair loss
• Changes in skin or nail color
• Missed menstrual periods

Serious Side Effects

Seek medical attention immediately if you experience any of the following serious symptoms:

• Blood in the urine or frequent, painful urination
• Signs of infection, such as fever, chills, or sore throat
• Unusual bruising or bleeding
• Shortness of breath or a persistent cough
• Swelling of the feet, ankles, or lower legs
• Chest pain or a fast, irregular heartbeat
• Yellowing of the skin or eyes
• Extreme tiredness or weakness

Cyclophosphamide can significantly lower the number of blood cells in your body, which increases the risk of infection and bleeding. It may also cause long-term effects such as infertility in both men and women or an increased risk of developing other types of cancer later in life.

Major Health Warnings

Cyclophosphamide can cause severe and potentially life-threatening complications. Healthcare providers monitor patients closely for the following risks:

• Bone Marrow Suppression: This medication can significantly lower the levels of white blood cells, red blood cells, and platelets. This increases the risk of serious infections, anemia, and easy bruising or bleeding. Regular blood tests are required to monitor these levels.
• Bladder and Urinary Tract Toxicity: Hemorrhagic cystitis (inflammation and bleeding of the bladder) is a serious risk. Maintaining high fluid intake and frequent urination are often recommended to help prevent this. Blood in the urine should be reported immediately.
• Secondary Malignancies: Treatment may increase the risk of developing other types of cancer later in life, such as bladder cancer, leukemia, or lymphoma.
• Heart and Lung Damage: High doses can lead to heart failure or lung scarring (pulmonary fibrosis), which may be fatal.

Pregnancy and Fertility

Cyclophosphamide can cause permanent infertility in both men and women. It can also cause severe harm or death to an unborn baby if used during pregnancy. Effective birth control is required during treatment and for a specified period after the final dose. Breastfeeding is not recommended during treatment.

Contraindications

This medication is generally not used in individuals who have:

• A known severe allergic reaction to cyclophosphamide.
• Severely suppressed bone marrow function.
• Obstructions in the urinary tract.

Monitoring and Precautions

Healthcare providers will perform regular monitoring throughout treatment, including frequent blood counts and urinalysis to check for blood. Kidney and liver function, as well as electrolyte levels, are also typically monitored to ensure the medication is being processed safely.

Pregnancy Risks

Cyclophosphamide can cause significant harm to a developing fetus, including birth defects and miscarriage. It is generally avoided during pregnancy. If you are pregnant or planning to become pregnant, it is important to discuss the potential risks and benefits of this treatment with your healthcare provider.

Contraception and Fertility

Due to the risk of fetal harm, healthcare providers recommend using effective contraception during and after treatment:

• Women of reproductive potential should use effective birth control during treatment and for at least one year after the final dose.
• Men with female partners who can become pregnant should use effective birth control, such as condoms, during treatment and for at least six months after the final dose.

Cyclophosphamide may also cause permanent infertility in both men and women by affecting the ovaries or sperm production. Discuss fertility preservation options with a doctor before beginning therapy.

Breastfeeding

This medication passes into breast milk and could cause serious adverse reactions in a nursing infant. Healthcare providers typically advise against breastfeeding during treatment and for at least one week following the last dose.

Available Forms

Cyclophosphamide is supplied in the following dosage forms:

• Oral Tablets: These are intended for administration by mouth.
• Injection for Intravenous Use: This form is administered by a healthcare professional into a vein. It is available as a powder that must be dissolved and diluted or as a solution ready for dilution and infusion.

FDA Approval and Indications

Cyclophosphamide is an FDA-approved prescription medication classified as an alkylating agent. It is indicated for the treatment of several types of cancer, including malignant lymphomas, multiple myeloma, various forms of leukemia, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma.

The medication is also approved for use in pediatric patients with minimal change nephrotic syndrome. This use is generally reserved for cases where the disease has not responded adequately to corticosteroid treatment or when side effects from steroids are not tolerable.

Safety and Regulatory Oversight

While cyclophosphamide does not carry a formal Boxed Warning, the FDA-approved labeling includes significant warnings regarding its potential for serious toxicity. Key regulatory safety concerns include:

• Myelosuppression: The drug can cause severe bone marrow suppression, increasing the risk of life-threatening infections and bleeding.
• Urinary Tract Toxicity: Hemorrhagic cystitis and other bladder complications are known risks, often requiring preventative measures like increased fluid intake.
• Secondary Malignancies: Long-term use is associated with an increased risk of developing secondary cancers, such as bladder cancer or acute leukemia.
• Reproductive Risks: The FDA labeling indicates potential for fetal harm and infertility in both men and women.

There is currently no Risk Evaluation and Mitigation Strategy (REMS) required for this medication.

Breastfeeding Risks

Cyclophosphamide is known to pass into human breast milk. Because this medication can cause severe adverse reactions in a nursing child, healthcare providers advise against breastfeeding while receiving treatment.

Potential risks to an infant exposed to cyclophosphamide through breast milk include:

• Low white blood cell counts (neutropenia)
• Low platelet counts (thrombocytopenia)
• Low hemoglobin levels
• Diarrhea

Due to these safety concerns, it is generally recommended to avoid breastfeeding during treatment and for at least one week after the final dose is administered. This waiting period helps ensure the medication has sufficiently cleared from the body before the infant is exposed to breast milk again.